13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • WO39210

    Acronym: 

    WO39210

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III Tumour Stream Kidney
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Kidney
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase III , multicenter, randomised placebo-controlled, double-blind study of Atezolizumab (Anti-PD-L1 Antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy

    Lay Summary

    Sponsor / Cooperative group

    Roche

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting